Drugs / INNA-051
Trials 3
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2 | NCT07222670 | Dec 2025 → Feb 2027 expected | viral respiratory tract infection | ENA Respiratory Pty Ltd | Recruiting | No outcome recorded |
| Phase 2 | NCT05118763 | Mar → Dec 2022 | COVID-19 | ENA Respiratory Pty Ltd | Withdrawn | No outcome recorded Stop: Business |
| Phase 2 | NCT05255822 | Feb → Aug 2022 | — | ENA Respiratory Pty Ltd | Completed | No outcome recorded |
News releases announcing trial results or a regulatory action · 9
| Date | Issuer | Release |
|---|---|---|
| 2025-04-02 | ENA Respiratory Pty Ltd | Results ENA Respiratory Announces Publication Supporting the Potential of its Novel Intranasal Therapy INNA-051 to Reduce the Impact of Viral Respiratory Infections in Older Adults enarespiratory.com ↗
Biomarker analysis showed that INNA-051 triggered host defence pathways within eight hours of each dose. |
| 2025-01-22 | ENA Respiratory Pty Ltd | Results ENA Respiratory Successfully Completes Phase Ib Dosing of Antiviral Host Defense Immune Enhancer INNA-051 Dry Powder Formulation in Older Adults and Advances Study in Young Adults enarespiratory.com ↗
Intranasal administration of the novel and more stable formulation of INNA-051 was well-tolerated and led to local activation of innate immune pathways gene expression. |
| 2024-12-18 | ENA Respiratory Pty Ltd | Results ENA Respiratory Announces Peer-Reviewed Publication of First Time in Humans and Influenza Virus Challenge Studies with the Intranasal Innate Immunomodulator INNA-051 enarespiratory.com ↗
When compared to placebo, prophylactic administration of INNA-051 was associated with significantly increased expression of multiple host defense genes and shorter duration of infection in influenza virus-infected individuals |
| 2024-05-08 | ENA Respiratory Pty Ltd | Regulatory ENA Respiratory Receives USPTO Notice of Allowance for Key Patent Covering INNA-051, a First-in-Class Antiviral Innate Immunomodulator enarespiratory.com ↗ |
| 2024-04-29 | ENA Respiratory Pty Ltd | Regulatory ENA Respiratory Announces FDA IND Clearance for its Prophylactic Intranasal INNA-051 – a First-in-Class Antiviral Innate Immunomodulator enarespiratory.com ↗
ENA Respiratory Announces FDA IND Clearance for its Prophylactic Intranasal INNA-051 – a First-in-Class Antiviral Innate Immunomodulator |
| 2023-09-11 | ENA Respiratory Pty Ltd | Results New Data From an Influenza Challenge Study Further Support the Prophylactic Potential of INNA-051 to Accelerate Viral Clearance enarespiratory.com ↗
New data reported today show that in this population, INNA-051 resulted in early stimulation of multiple genes that play important roles in the response to viral infections, including type I and III interferons. |
| 2023-02-14 | ENA Respiratory Pty Ltd | Results Nasal Spray Significantly Accelerates Respiratory Virus Clearance in Phase 2a Clinical Study enarespiratory.com ↗
Post hoc analyses excluding those with pre-existing immunity showed that INNA-051-treated participants with PCR laboratory-confirmed infection had a statistically significant shorter duration of infection. |
| 2021-12-18 | ENA Respiratory Pty Ltd | Results ENA Respiratory announces research on preventative nasal spray, which protects against COVID-19 and common cold, published in leading peer-reviewed academic journals enarespiratory.com ↗
Research on a novel nasal spray therapy, INNA-051, which has been shown to reduce COVID-19 viral replication by up to 96 percent in a gold standard ferret study, has been published in two leading international peer-reviewed journals. |
| 2020-09-28 | ENA Respiratory Pty Ltd | Results ENA Respiratory announces an extension of its Series A and positive COVID-19 ferret challenge study results enarespiratory.com ↗
By boosting the immune response in this way with INNA-051 prior to infection, the ability of the COVID-19 virus to infect the animals and replicate was dramatically reduced the PHE study showed. |
All press releases naming this drug 21 releases
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 3 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | INNA-051 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05118763 ↗ |
| Action | Activate | “INNA-051, a TLR2/6 agonist” NCT07222670 ↗ |
| Route | Intranasal | “INNA-051 intranasal spray low dose administered once on each of Days 1, 4, 7 and 10” NCT05118763 ↗ |
| Target | TLR2 | “INNA-051, a TLR2/6 agonist” NCT07222670 ↗ |